Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is “One to Watch”
Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete Processa’s current development pipeline features multiple clinical drug candidates, given the recent acquisitions of three additional development-focused licensing agreement since June 2020 In total, the company’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and…
